Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
14,84 USD | -4,26 % | +0,27 % | +35,53 % |
Resumen de negocios
Número de empleados: 157
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Cancer Immunotherapies
100,0
%
| 268 | 100,0 % | 13 | 100,0 % | -95,29 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States and Belgium
100,0
%
| 268 | 100,0 % | 13 | 100,0 % | -95,29 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 01/04/12 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 01/06/20 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 01/05/20 |
Matthew Call
COO | Chief Operating Officer | 51 | 01/08/19 |
Adi Osovsky
LAW | General Counsel | - | 01/06/21 |
Human Resources Officer | - | 01/01/20 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 01/06/20 |
David Hallal
CHM | Chairman | 56 | 01/06/18 |
Director/Board Member | 52 | 01/06/18 | |
Jill DeSimone
BRD | Director/Board Member | 68 | 07/03 |
Michel Detheux
FOU | Founder | 57 | 01/04/12 |
Robert Iannone
BRD | Director/Board Member | 57 | 03/04/21 |
Tony Ho
BRD | Director/Board Member | 58 | 03/04/21 |
Aaron Davis
BRD | Director/Board Member | 45 | 01/03/20 |
David Lee
BRD | Director/Board Member | 42 | 05/12 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 36 122 922 | 35 868 332 ( 99,30 %) | 0 | 99,30 % |
Información de la empresa
Sector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+35,53 % | 553 M | |
+15,20 % | 121 mil M | |
+19,67 % | 113 mil M | |
+18,95 % | 26,02 mil M | |
-23,86 % | 19,39 mil M | |
-19,03 % | 15,91 mil M | |
-20,90 % | 15,09 mil M | |
-46,14 % | 15,06 mil M | |
+63,85 % | 14,93 mil M | |
+4,49 % | 13,85 mil M |
- Bolsa de valores
- Acciones
- Acción ITOS
- Empresa iTeos Therapeutics, Inc.